Vertex Pharmaceuticals has a virtual monopoly in treating cystic fibrosis, having created and brought to market a function cure for 90% of the CF population. Their pipeline outside of CF has shown ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Making a noteworthy insider sell on November 12, ITEM SECOND IRR TRUST FBO JACOB J WESTPHAL ua of JEFFREY R WESTPHAL dated October , 10% Owner at Vertex (NASDAQ:VERX), is reported in the latest ...

Jeffrey Westphal, 10% Owner at Vertex VERX, executed a substantial insider sell on November 14, according to an SEC filing. Vertex shares are trading up 0.43% at $50.8 at the time of this writing ...

Vertex Pharmaceuticals is in the process of getting a new painkiller approved. It just published some data that suggests the candidate will be quite profitable. But regulators still need to sign ...

But there was one company that kept at it. Fast-forward to today, and Vertex Pharmaceuticals is on the verge of gaining an FDA approval for suzetrigine (VX-548), a nonaddictive oral treatment that ...

Vertex has reported phase 3 data on its near-approval pain drug candidate suzetrigine, shedding light on how the non-opioid painkiller combines with ibuprofen and why the prospect failed to match ...

Jeffrey Westphal, 10% Owner at Vertex (NASDAQ:VERX), executed a substantial insider sell on November 14, according to an SEC filing. What Happened: Westphal's recent move involves selling ...

Vertex Flashes A Surprise Buy Point As Non-Opioid Pain Drug Looms Vertex beat Wall Street's third-quarter expectations, but the real story for Vertex stock is still to come, analysts said Tuesday ...

Vertex beat Wall Street's third-quarter expectations, but the real story for Vertex stock is still to come, analysts said Tuesday. Meet the Newest Addition to the S&P 500. The Stock Has Soared 845 ...